Prescient Therapeutics Limited (AU:PTX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited reported a 49.8% increase in revenues to $687,577 for the fiscal year ended June 30, 2024, alongside a 17.6% rise in net loss to $8,238,050, with no dividends issued. The company’s net assets decreased significantly due to increased R&D, corporate, and employment expenses, despite an estimated R&D incentive rebate of $3,712,364.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.